Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2020; 78(05): 315
DOI: 10.1590/0004-282x20200029
LETTER

Reply

Resposta
Lineu Cesar WERNECK 
1   Universidade Federal do Paraná, Hospital de Clínicas, Serviço de Doenças Neuromusculares, Curitiba PR, Brazil.
,
Paulo José LORENZONI 
1   Universidade Federal do Paraná, Hospital de Clínicas, Serviço de Doenças Neuromusculares, Curitiba PR, Brazil.
,
Renata Dal-Prá DUCCI 
1   Universidade Federal do Paraná, Hospital de Clínicas, Serviço de Doenças Neuromusculares, Curitiba PR, Brazil.
,
Otto Hernández FUSTES 
1   Universidade Federal do Paraná, Hospital de Clínicas, Serviço de Doenças Neuromusculares, Curitiba PR, Brazil.
,
Cláudia Suemi Kamoi KAY 
1   Universidade Federal do Paraná, Hospital de Clínicas, Serviço de Doenças Neuromusculares, Curitiba PR, Brazil.
,
Rosana Herminia SCOLA 
1   Universidade Federal do Paraná, Hospital de Clínicas, Serviço de Doenças Neuromusculares, Curitiba PR, Brazil.
› Author Affiliations
› Further Information
Also available at
  Permissions and Reprints

We thank Dr. Josef Finsterer for his comments that completed our paper[1].

The scope of the paper was to present a review of pharmacological therapy of Duchenne muscular dystrophy (DMD). We agree that the points raised by Dr. Finsterer are very important, as we point out in the conclusion of the paper. Due to policies of the Arquivos de Neuropsiquiatria, the paper was in the limit of words and references for review articles. For this reason, it was not possible to extend the discussion about investigation and treatment of other aspects of DMD as he has pointed out and as it is performed in our center[2],[3].



Publication History

Received: 24 March 2020

Accepted: 25 March 2020

Article published online:
13 June 2023

© 2020. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Werneck LC, Lorenzoni PJ, Ducci RD, Fustes OH, Kay CSK, Scola RH. Duchenne muscular dystrophy: an historical treatment review. Arq Neuropsiquiatr. 2019 Sep;77(8):579-89. https://doi.org/10.1590/0004-282X20190088
  • 2 Cirino RHD, Scola RH, Ducci RD, Wermelinger ACC, Kay CSK, Lorenzoni PJ, et al. Predictors of early left ventricular systolic dysfunction in Duchenne muscular dystrophy. Muscle Nerve. 2018 Jul;58(1):84-9. https://doi.org/10.1002/mus.26102
  • 3 Cirino RHD, Scola RH, Ducci RD, Camarozano AC, Kay CSK, Lorenzoni PJ, et al. Evaluation of left-sided heart chambers with novel echochardiographic techniques in men with Duchenne and Becker muscular dystrophy. Am J Cardiol. 2019 Mar;123(6):972-8. https://doi.org/10.1016/j.amjcard.2018.12.011